5f4n | pdb_00005f4n
From Proteopedia
Unreleased structure
The entry 5f4n is ON HOLD
Authors: Collins, I., Garrett, M.D., van Montfort, R., Osborne, J.D., Matthews, T.P., McHardy, T., Proisy, N., Cheung, K.J., Lainchbury, M., Brown, N., Walton, M.I., Eve, P.D., Boxall, K.J., Hayes, A., Henley, A.T., Valenti, M.R., De Haven Brandon, A.K., Box, G., Westwood, I.M., Jamin, Y., Robinson, S.P., Leonard, P., Reader, J.C., Aherne, G.W., Raynaud, F.I., Eccles, S.A.
Description: Multi-parameter lead optimization to give an oral CHK1 inhibitor clinical candidate: (R)-5-((4-((morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)
Proteopedia Page Contributors and Editors (what is this?)
Categories:
- Unreleased Structures
- Mchardy, T
- Cheung, K.J
- Hayes, A
- Lainchbury, M
- Proisy, N
- Collins, I
- Westwood, I.M
- Henley, A.T
- Reader, J.C
- Aherne, G.W
- Raynaud, F.I
- Eccles, S.A
- Box, G
- De Haven Brandon, A.K
- Walton, M.I
- Robinson, S.P
- Jamin, Y
- Van Montfort, R
- Brown, N
- Leonard, P
- Eve, P.D
- Valenti, M.R
- Boxall, K.J
- Osborne, J.D
- Garrett, M.D
- Matthews, T.P
